EBV-CTL: Phase II data

The open-label, U.S. Phase II 11-130 trial in 18 patients with EBV-positive lymphoproliferative disorder who were recipients of once-weekly infusions of 1 or 2 x 106 cells/kg of third-party EBV-CTLs f...